Eight‐year follow‐up in pediatric living donor kidney recipients receiving alemtuzumab induction

Recipient lymphocytes are crucial for direct and indirect pathways of allorecognition. We proposed that the administration of alemtuzumab several weeks pretransplantation could eradicate peripheral lymphatic cells and promote donor‐specific acceptance. This was a single‐center, retrospective review...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric transplantation 2017-08, Vol.21 (5), p.n/a
Hauptverfasser:	Kaabak, Michael M., Babenko, Nadeen N., Shapiro, Ron, Maschan, Alexey A., Zokoev, Allan K., Schekaturov, Stanislav V., Vyunkova, Julia N., Dymova, Olga V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Alemtuzumab - administration & dosage Alemtuzumab - therapeutic use alemtuzumab induction therapy Biopsy Child Child, Preschool Cyclosporins Drug Administration Schedule Female Follow-Up Studies Graft rejection Graft Rejection - diagnosis Graft Rejection - epidemiology Graft Rejection - prevention & control Graft Survival Humans Immunosuppression Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Immunotherapy Induction Chemotherapy - methods Infant Kidney transplantation Kidney Transplantation - methods live donor Living Donors long‐term results Lymphocytes Maintenance Chemotherapy - methods Male Monoclonal antibodies Mycophenolic acid pediatric kidney transplantation Pediatrics Perioperative Care - methods Retrospective Studies Steroid hormones steroid‐free immunosuppression Survival Tacrolimus Transplantation Transplants & implants Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!